Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Taurolidine And Heparin · Defencath

Small molecule · Acts on Antithrombin III (SERPINC1) · developed by Cormedix

Approved FDA, Nov 2023
CRMD Developer
1 Registered trials

What is Taurolidine And Heparin?

Taurolidine and Heparin (DefenCath) is a combination of taurolidine, an antimicrobial thiadiazinane, and heparin, an anticoagulant that enhances antithrombin III activity to inhibit clotting factors Xa and IIa. It is used in catheter lock solution to reduce catheter-related bloodstream infections in adults with kidney failure receiving chronic hemodialysis through a central venous catheter.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Defencath, DefenCath
Drug type
Small molecule
Targets
Antithrombin III (SERPINC1) (binding partner it blocks), Coagulation factor Xa (F10) (secondary target), Thrombin (coagulation factor IIa) (F2) (secondary target)
Mechanism
Acts on Antithrombin III (SERPINC1)
Pathways
coagulation cascade, fibrin clot formation
Therapy area
Infectious disease, Renal & urology
Developer
Cormedix (CRMD)
FDA status
Approved as Defencath (November 15, 2023), NDA214520 · FDA label

✅ FDA-approved uses

From the indications section of the FDA label (version of Sep 4, 2026). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06707480 N/A Catheter-related Bloodstream Infection No longer available CRMD

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Catheter-related Bloodstream Infection

Other drugs acting on SERPINC1

More from Cormedix

Sources

Updated Nov 8, 2026. Something wrong or missing? Report it on the CRMD page.

Follow CRMD, the company behind Taurolidine And Heparin

See CRMD's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

CRMD catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.